Abbonarsi

Targets and strategies for vaccine development against SARS-CoV-2 - 19/03/21

Doi : 10.1016/j.biopha.2021.111254 
Jonaid Ahmad Malik a, b, Almas Hanif Mulla c, Tahmeena Farooqi d, Faheem Hyder Pottoo e, , Sirajudheen Anwar f, Kannan R.R. Rengasamy g, h, i,
a Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Guwahati, Assam, India 
b Department of Biomedical Engineering, Indian Institute of Technology (IIT), Ropar, Punjab, India 
c Department of Pharmacology, Goa College of Pharmacy, Goa, India 
d Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research, Hyderabad Telangana, India 
e Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O.BOX 1982, Dammam, 31441, Saudi Arabia 
f Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, 81442, Saudi Arabia 
g Institute of Research and Development, Duy Tan University, Da Nang, 550000, Viet Nam 
h Faculty of Environment and Chemical Engineering, Duy Tan University, Da Nang, 550000, Viet Nam 
i Indigenous Knowledge Systems Centre, Faculty of Natural and Agricultural Sciences, North-West University, Private Bag X2046, Mmabatho, 2745, North West Province, South Africa 

Corresponding authors at: Institute of Research and Development, Duy Tan University, Da Nang 550000, Viet Nam.Institute of Research and DevelopmentDuy Tan UniversityDa Nang550000Viet Nam

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Highlights

The potential antigen targets are being utilized for the formulation of an effective vaccine. Spike protein is the most utilized antigen target for vaccine development, however other structural and non-structural proteins are also considered potent targets.
Several clinical trials, for the SARS-CoV-2 vaccine, are ongoing. However a varying number of challenges are being encountered during the process of vaccine development, manufacturing, and mass distribution.
Conventional vaccination strategies pose toxicities, novel platforms for SARS-CoV-2 vaccines are proving to be effective and safe in larger clinical trials.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

The SARS-CoV-2, previously called a novel coronavirus, that broke out in the Wuhan city of China caused a significant number of morbidity and mortality in the world. It is spreading at peak levels since the first case reported and the need for vaccines is in immense demand globally. Numerous treatment and vaccination strategies that were previously employed for other pathogens including coronaviruses are now being been adopted to guide the formulation of new SARS-CoV-2 vaccines. Several vaccine targets can be utilized for the development of the SARS-CoV-2 vaccine. In this review, we highlighted the potential of various antigenic targets and other modes for formulating an effective vaccine against SARS-CoV-2. There are a varying number of challenges encountered during developing the most effective vaccines, and measures for tackling such challenges will assist in fast pace development of vaccines. This review will give a concise overview of various aspects of the vaccine development process against SARS-CoV-2, including 1) potential antigen targets 2) different vaccination strategies from conventional to novel platforms, 3) ongoing clinical trials, 4) varying challenges encountered during developing the most effective vaccine and the futuristic approaches.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : Acad, Ads, AdCs, ADMP, ADE, ADDE, ARDS, CD4+ (T cells), CD8+ (T cells), CTD, FP, E, FLSP, GP 96, GNVAM, HLA, hACE 2, HCR, HIRs, Ins, LUNAR, LVVV, LTAEs, LNP, MMR, MVA, MHC, MIDRT, MSA, MSC, NIH, NTD, NRVV, ORF, OPV, RBD, PEI, PLA, RBM, RSV, RSP, RDV, RDCA, SARS, SARS, SPs, S Protein, S2RBD, SRBD, S2E, S2M, S2N, STARR, S2E, SamRNA, SSRV, SIN, SPs, TCEBPI, TPA, Uni, VLP, VSV

Keywords : Vaccine, COVID-19, Clinical trials, SARS-CoV-2 vaccine, Pandemic, Antigen targets


Mappa


© 2021  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 137

Articolo 111254- maggio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Evidence and perspectives of cell senescence in neurodegenerative diseases
  • Zizhen Si, Linlin Sun, Xidi Wang
| Articolo seguente Articolo seguente
  • New insight and potential therapy for NAFLD: CYP2E1 and flavonoids
  • Kaiyue Wang, Wangxiao Tan, Xiao Liu, Lina Deng, Lu Huang, Xiaoying Wang, Xiumei Gao

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.